STOCK TITAN

[8-K] CareCloud, Inc. 8.75% Series A Cumulative Redeemable Perpetual Preferred Stock Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Lyell Immunopharma (LYEL) entered into a private placement agreement on 24-Jul-25.

Initial Closing (25-Jul-25): sale of 3,753,752 common shares at $13.32 for ≈$50 million gross proceeds.

Follow-on funding: the company may require investors to purchase another ≈$50 million within 12 months if the pivotal LYL314 PiNACLE trial or other corporate milestones are achieved ("Milestone Closing") at $25.61 per share, with a floor of $10.41. Investors can alternatively call the same dollar amount at $30.73 ("Investor Call Closing"). Ownership above 19.99 % converts excess into pre-funded warrants exercisable at $0.0001.

Lyell must file resale registration statements within 30 days of each closing; cash penalties apply for delays.

Use of proceeds: fund two pivotal LYL314 trials, working capital and general purposes. Management states the added capital should extend liquidity runway into mid-2027.

Lyell Immunopharma (LYEL) ha stipulato un accordo di collocamento privato il 24 luglio 2025.

Chiusura iniziale (25 luglio 2025): vendita di 3.753.752 azioni ordinarie a 13,32 $ ciascuna per un ricavo lordo di circa 50 milioni di dollari.

Finanziamento aggiuntivo: la società potrà richiedere agli investitori l'acquisto di ulteriori circa 50 milioni di dollari entro 12 mesi, se la prova cardine LYL314 PiNACLE o altri traguardi aziendali saranno raggiunti ("Chiusura per traguardo") a 25,61 $ per azione, con un prezzo minimo di 10,41 $. In alternativa, gli investitori potranno richiamare lo stesso importo a 30,73 $ per azione ("Chiusura per richiamo investitori"). La proprietà superiore al 19,99% convertirà l'eccesso in warrant prefinanziati esercitabili a 0,0001 $.

Lyell deve depositare le dichiarazioni di registrazione per la rivendita entro 30 giorni da ogni chiusura; sono previste penali in denaro per ritardi.

Utilizzo dei proventi: finanziare due studi pivotali LYL314, capitale circolante e scopi generali. Il management dichiara che il capitale aggiuntivo dovrebbe estendere la liquidità fino a metà 2027.

Lyell Immunopharma (LYEL) firmó un acuerdo de colocación privada el 24 de julio de 2025.

Cierre inicial (25 de julio de 2025): venta de 3.753.752 acciones comunes a 13,32 $ cada una, generando aproximadamente 50 millones de dólares en ingresos brutos.

Financiamiento adicional: la empresa podrá solicitar a los inversores la compra de otros ≈50 millones de dólares dentro de 12 meses si se logra el ensayo pivotal LYL314 PiNACLE u otros hitos corporativos (“Cierre por hito”) a 25,61 $ por acción, con un piso de 10,41 $. Alternativamente, los inversores pueden ejercer la misma cantidad en dólares a 30,73 $ (“Cierre por llamada del inversor”). La propiedad que supere el 19,99 % convertirá el exceso en warrants prefinanciados ejercitables a 0,0001 $.

Lyell debe presentar declaraciones de registro para la reventa dentro de los 30 días posteriores a cada cierre; se aplican multas en efectivo por retrasos.

Uso de los fondos: financiar dos ensayos pivotales LYL314, capital de trabajo y propósitos generales. La dirección indica que el capital adicional debería extender la liquidez hasta mediados de 2027.

Lyell Immunopharma (LYEL)는 2025년 7월 24일에 사모 배정 계약을 체결했습니다.

초기 마감 (2025년 7월 25일): 보통주 3,753,752주를 주당 13.32달러에 판매하여 약 5천만 달러의 총수익을 올렸습니다.

후속 자금 조달: 회사는 중추적인 LYL314 PiNACLE 임상시험 또는 기타 기업 목표가 달성될 경우 12개월 이내에 투자자에게 약 5천만 달러를 추가로 구매하도록 요청할 수 있습니다("마일스톤 마감"). 주당 가격은 25.61달러이며 최저가는 10.41달러입니다. 투자자는 대안으로 동일한 금액을 주당 30.73달러에 호출할 수 있습니다("투자자 호출 마감"). 소유 지분이 19.99%를 초과하면 초과분은 주당 0.0001달러에 행사 가능한 선지급 워런트로 전환됩니다.

Lyell은 각 마감일로부터 30일 이내에 재판매 등록 서류를 제출해야 하며, 지연 시 현금 벌금이 부과됩니다.

자금 사용처: 두 건의 중추적인 LYL314 임상시험, 운전자본 및 일반 목적 자금으로 활용됩니다. 경영진은 추가 자본이 2027년 중반까지 유동성 기간을 연장할 것으로 예상한다고 밝혔습니다.

Lyell Immunopharma (LYEL) a conclu un accord de placement privé le 24 juillet 2025.

Clôture initiale (25 juillet 2025) : vente de 3 753 752 actions ordinaires à 13,32 $ chacune, générant environ 50 millions de dollars de produits bruts.

Financement complémentaire : la société pourra demander aux investisseurs d'acheter environ 50 millions de dollars supplémentaires dans les 12 mois si l'essai pivot LYL314 PiNACLE ou d'autres jalons corporatifs sont atteints (« Clôture liée au jalon ») à 25,61 $ par action, avec un plancher à 10,41 $. Les investisseurs peuvent alternativement appeler le même montant en dollars à 30,73 $ (« Clôture par appel investisseur »). La détention au-delà de 19,99 % convertira l'excédent en bons de souscription préfinancés exerçables à 0,0001 $.

Lyell doit déposer les déclarations d'enregistrement pour la revente dans les 30 jours suivant chaque clôture ; des pénalités en espèces s'appliquent en cas de retard.

Utilisation des fonds : financer deux essais pivots LYL314, le fonds de roulement et des usages généraux. La direction indique que le capital supplémentaire devrait prolonger la trésorerie jusqu'à mi-2027.

Lyell Immunopharma (LYEL) hat am 24. Juli 2025 eine Privatplatzierungsvereinbarung getroffen.

Erstabschluss (25. Juli 2025): Verkauf von 3.753.752 Stammaktien zu je 13,32 $ mit einem Bruttoerlös von ca. 50 Millionen US-Dollar.

Folgefinanzierung: Das Unternehmen kann von Investoren verlangen, innerhalb von 12 Monaten weitere ca. 50 Millionen US-Dollar zu erwerben, falls die entscheidende LYL314 PiNACLE-Studie oder andere Unternehmensmeilensteine erreicht werden („Meilenstein-Abschluss“) zu 25,61 $ pro Aktie mit einem Mindestpreis von 10,41 $. Alternativ können Investoren denselben Betrag zu 30,73 $ pro Aktie abrufen („Investor Call-Abschluss“). Besitzanteile über 19,99 % werden überschüssig in vorfinanzierte Warrants umgewandelt, die zu 0,0001 $ ausgeübt werden können.

Lyell muss innerhalb von 30 Tagen nach jedem Abschluss Wiederverkaufsregistrierungen einreichen; bei Verzögerungen werden Geldstrafen fällig.

Verwendung der Erlöse: Finanzierung von zwei entscheidenden LYL314-Studien, Betriebskapital und allgemeine Zwecke. Das Management gibt an, dass das zusätzliche Kapital die Liquiditätsreichweite bis Mitte 2027 verlängern sollte.

Positive
  • $50 million immediate capital secured, with an additional $50 million available on milestone achievement.
  • Cash runway extended to mid-2027, covering pivotal LYL314 trials.
  • Milestone-linked pricing aligns investor commitment with clinical progress, potentially limiting cost of capital.
Negative
  • Share dilution from 3.75 million new shares and potential future issuances.
  • Price floor of $10.41 could force capital raise at a steep discount if share price weakens.
  • Registration-statement penalties and investor rescission rights place compliance and timing risk on the company.

Insights

TL;DR – $50 m now, up to $100 m more later; dilution traded for longer runway.

The agreement immediately boosts cash by $50 m and could double with milestone or investor call closings, materially extending liquidity to mid-2027. Pricing tiers add flexibility but embed dilution risk (floor $10.41). Warrants at $0.0001 cap ownership yet further expand share count. Registration-failure penalties and potential rescission rights protect investors, shifting execution risk to Lyell. Overall impact is capital-positive but valuation-dilutive; neutral on balance.

TL;DR – Financing aligned with pivotal LYL314 timeline; milestone clause signals confidence.

Tying the second $50 m tranche to PiNACLE results incentivises continued progress on LYL314, Lyell’s lead asset. The optional investor call price of $30.73 implies upside expectations if data are strong. Cash runway into 2027 covers trial read-outs and potential regulatory filings, reducing near-term financing overhang. Execution risk remains, yet the structure suggests supportive long-term holders. Net effect: modestly positive for clinical strategy and balance-sheet strength.

Lyell Immunopharma (LYEL) ha stipulato un accordo di collocamento privato il 24 luglio 2025.

Chiusura iniziale (25 luglio 2025): vendita di 3.753.752 azioni ordinarie a 13,32 $ ciascuna per un ricavo lordo di circa 50 milioni di dollari.

Finanziamento aggiuntivo: la società potrà richiedere agli investitori l'acquisto di ulteriori circa 50 milioni di dollari entro 12 mesi, se la prova cardine LYL314 PiNACLE o altri traguardi aziendali saranno raggiunti ("Chiusura per traguardo") a 25,61 $ per azione, con un prezzo minimo di 10,41 $. In alternativa, gli investitori potranno richiamare lo stesso importo a 30,73 $ per azione ("Chiusura per richiamo investitori"). La proprietà superiore al 19,99% convertirà l'eccesso in warrant prefinanziati esercitabili a 0,0001 $.

Lyell deve depositare le dichiarazioni di registrazione per la rivendita entro 30 giorni da ogni chiusura; sono previste penali in denaro per ritardi.

Utilizzo dei proventi: finanziare due studi pivotali LYL314, capitale circolante e scopi generali. Il management dichiara che il capitale aggiuntivo dovrebbe estendere la liquidità fino a metà 2027.

Lyell Immunopharma (LYEL) firmó un acuerdo de colocación privada el 24 de julio de 2025.

Cierre inicial (25 de julio de 2025): venta de 3.753.752 acciones comunes a 13,32 $ cada una, generando aproximadamente 50 millones de dólares en ingresos brutos.

Financiamiento adicional: la empresa podrá solicitar a los inversores la compra de otros ≈50 millones de dólares dentro de 12 meses si se logra el ensayo pivotal LYL314 PiNACLE u otros hitos corporativos (“Cierre por hito”) a 25,61 $ por acción, con un piso de 10,41 $. Alternativamente, los inversores pueden ejercer la misma cantidad en dólares a 30,73 $ (“Cierre por llamada del inversor”). La propiedad que supere el 19,99 % convertirá el exceso en warrants prefinanciados ejercitables a 0,0001 $.

Lyell debe presentar declaraciones de registro para la reventa dentro de los 30 días posteriores a cada cierre; se aplican multas en efectivo por retrasos.

Uso de los fondos: financiar dos ensayos pivotales LYL314, capital de trabajo y propósitos generales. La dirección indica que el capital adicional debería extender la liquidez hasta mediados de 2027.

Lyell Immunopharma (LYEL)는 2025년 7월 24일에 사모 배정 계약을 체결했습니다.

초기 마감 (2025년 7월 25일): 보통주 3,753,752주를 주당 13.32달러에 판매하여 약 5천만 달러의 총수익을 올렸습니다.

후속 자금 조달: 회사는 중추적인 LYL314 PiNACLE 임상시험 또는 기타 기업 목표가 달성될 경우 12개월 이내에 투자자에게 약 5천만 달러를 추가로 구매하도록 요청할 수 있습니다("마일스톤 마감"). 주당 가격은 25.61달러이며 최저가는 10.41달러입니다. 투자자는 대안으로 동일한 금액을 주당 30.73달러에 호출할 수 있습니다("투자자 호출 마감"). 소유 지분이 19.99%를 초과하면 초과분은 주당 0.0001달러에 행사 가능한 선지급 워런트로 전환됩니다.

Lyell은 각 마감일로부터 30일 이내에 재판매 등록 서류를 제출해야 하며, 지연 시 현금 벌금이 부과됩니다.

자금 사용처: 두 건의 중추적인 LYL314 임상시험, 운전자본 및 일반 목적 자금으로 활용됩니다. 경영진은 추가 자본이 2027년 중반까지 유동성 기간을 연장할 것으로 예상한다고 밝혔습니다.

Lyell Immunopharma (LYEL) a conclu un accord de placement privé le 24 juillet 2025.

Clôture initiale (25 juillet 2025) : vente de 3 753 752 actions ordinaires à 13,32 $ chacune, générant environ 50 millions de dollars de produits bruts.

Financement complémentaire : la société pourra demander aux investisseurs d'acheter environ 50 millions de dollars supplémentaires dans les 12 mois si l'essai pivot LYL314 PiNACLE ou d'autres jalons corporatifs sont atteints (« Clôture liée au jalon ») à 25,61 $ par action, avec un plancher à 10,41 $. Les investisseurs peuvent alternativement appeler le même montant en dollars à 30,73 $ (« Clôture par appel investisseur »). La détention au-delà de 19,99 % convertira l'excédent en bons de souscription préfinancés exerçables à 0,0001 $.

Lyell doit déposer les déclarations d'enregistrement pour la revente dans les 30 jours suivant chaque clôture ; des pénalités en espèces s'appliquent en cas de retard.

Utilisation des fonds : financer deux essais pivots LYL314, le fonds de roulement et des usages généraux. La direction indique que le capital supplémentaire devrait prolonger la trésorerie jusqu'à mi-2027.

Lyell Immunopharma (LYEL) hat am 24. Juli 2025 eine Privatplatzierungsvereinbarung getroffen.

Erstabschluss (25. Juli 2025): Verkauf von 3.753.752 Stammaktien zu je 13,32 $ mit einem Bruttoerlös von ca. 50 Millionen US-Dollar.

Folgefinanzierung: Das Unternehmen kann von Investoren verlangen, innerhalb von 12 Monaten weitere ca. 50 Millionen US-Dollar zu erwerben, falls die entscheidende LYL314 PiNACLE-Studie oder andere Unternehmensmeilensteine erreicht werden („Meilenstein-Abschluss“) zu 25,61 $ pro Aktie mit einem Mindestpreis von 10,41 $. Alternativ können Investoren denselben Betrag zu 30,73 $ pro Aktie abrufen („Investor Call-Abschluss“). Besitzanteile über 19,99 % werden überschüssig in vorfinanzierte Warrants umgewandelt, die zu 0,0001 $ ausgeübt werden können.

Lyell muss innerhalb von 30 Tagen nach jedem Abschluss Wiederverkaufsregistrierungen einreichen; bei Verzögerungen werden Geldstrafen fällig.

Verwendung der Erlöse: Finanzierung von zwei entscheidenden LYL314-Studien, Betriebskapital und allgemeine Zwecke. Das Management gibt an, dass das zusätzliche Kapital die Liquiditätsreichweite bis Mitte 2027 verlängern sollte.

false 0001582982 0001582982 2025-07-24 2025-07-24 0001582982 CCLD:CommonStockParValue0.001PerShareMember 2025-07-24 2025-07-24 0001582982 CCLD:Sec8.75SeriesBCumulativeRedeemablePerpetualPreferredStockParValue0.001PerShareMember 2025-07-24 2025-07-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): July 24, 2025

 

CARECLOUD, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-36529   22-3832302

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

7 Clyde Road, Somerset, New Jersey, 08873
(Address of principal executive offices, zip code)

 

(732) 873-5133

(Registrant’s telephone number, including area code)

 

Not Applicable
(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.001 per share   CCLD   Nasdaq Global Market
8.75% Series B Cumulative Redeemable Perpetual Preferred Stock, par value $0.001 per share   CCLDO   Nasdaq Global Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 7.01 Regulation FD Disclosure.

 

The Registrant is hereby furnishing the following information under Regulation FD:

 

On July 25, 2025, the Registrant issued a press release announcing that its Board of Directors declared monthly cash dividends for its Series A Cumulative Redeemable Perpetual Preferred Stock and its Series B Cumulative Redeemable Perpetual Preferred Stock for July, August and September 2025.

 

The foregoing description of the dividend payment does not purport to be complete and is explained in the press release, attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

 

Safe Harbor Statement

 

Statements contained in the exhibit that state the Company’s or its management’s expectations or predictions of the future are forward-looking statements intended to be covered by the safe harbor provisions of the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended. It is important to note that the Registrant’s actual results could differ materially from those projected in such forward-looking statements. The Registrant does not assume any obligations to update any of the forward-looking statements contained in the exhibit to reflect events that occur or circumstances that exist after the date on which they were made.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

99.1 Press release dated July 25, 2025.
   
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

2 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    CareCloud, Inc.
     
Date: July 25, 2025 By: /s/ Norman Roth
      Norman Roth
      Interim Chief Financial Officer and Corporate Controller

 

3 

FAQ

What did Lyell Immunopharma (LYEL) announce in its latest 8-K?

A $50 million private placement with the option to raise another $50 million tied to clinical milestones.

How many shares are being sold and at what price?

3,753,752 common shares at $13.32 per share in the initial closing.

What triggers the additional $50 million "Milestone Closing"?

Achievement of specified milestones, including progress in the pivotal LYL314 PiNACLE trial, within 12 months.

How will Lyell use the proceeds from the private placement?

To fund two pivotal-stage LYL314 clinical trials, working capital and general corporate purposes.

How long will the new funding support Lyell's operations?

Management expects liquidity to last into mid-2027 after the initial closing.

Are the securities registered with the SEC?

No; the shares are issued under Section 4(a)(2). Lyell will file resale registration statements within 30 days.
Carecloud Inc

NASDAQ:CCLDP

CCLDP Rankings

CCLDP Latest News

CCLDP Latest SEC Filings

CCLDP Stock Data

4.52M
103.94%
Health Information Services
Services-prepackaged Software
Link
United States
SOMERSET